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Glutamate, the main excitatory neurotransmitter in the central nervous system, exerts its effect through
ionotropic and metabotropic receptors. Of these, group III mGlu receptors (mGlu 4, 6, 7, 8) are among the
least studied due to a lack of pharmacological tools. mGlu7 receptors, the most highly conserved isoform,
are abundantly distributed in the brain, especially in regions, such as the amygdala, known to be crucial
for the emotional processing of painful stimuli. Visceral hypersensitivity is a poorly understood phe-
nomenon manifesting as an increased sensitivity to visceral stimuli. Glutamate has long been associated
with somatic pain processing leading us to postulate that crossover may exist between these two mo-
dalities. Moreover, stress has been shown to exacerbate visceral pain. ADX71743 is a novel, centrally
penetrant, negative allosteric modulator of mGlu7 receptors. Thus, we used this tool to explore the
possible involvement of this receptor in the mediation of visceral pain in a stress-sensitive model of
visceral hypersensitivity, namely the Wistar Kyoto (WKY) rat. ADX71743 reduced visceral hypersensi-
tivity in the WKY rat as exhibited by increased visceral sensitivity threshold with concomitant reductions
in total number of pain behaviours. Moreover, AD71743 increased total distance and distance travelled in
the inner zone of the open ﬁeld. These ﬁndings show, for what is to our knowledge, the ﬁrst time, that
mGlu7 receptor signalling plays a role in visceral pain processing. Thus, negative modulation of the
mGlu7 receptor may be a plausible target for the amelioration of stress-induced visceral pain where
there is a large unmet medical need.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Glutamate signalling has long been implicated in the patho-
physiology of pain states (Fundytus, 2001). Visceral pain is among
the most poorly understood pain modality characterised by
enhanced sensitivity to visceral stimuli. There is a dearth of infor-
mation regarding the underlying mechanisms of visceral pain,
however central sensitisation via excessive glutamatergic signalling
has been implicated (Cervero, 2009, 1995). Stress has been shown
to be a critical factor in visceral pain pathophysiology, both in terms
of increasing the risk to develop visceral hypersensitivity, and an
exacerbating or perpetuating factor (Chaloner and Greenwood-Vancience, Room 386, Western
d., Cork, Ireland.
r Inc. This is an open access articleMeerveld, 2013; Larauche et al., 2012; Johnson and Greenwood-Van
Meerveld, 2014; Lee et al., 2015; Prusator and Greenwood-Van
Meerveld, 2015; Hong et al., 2015; Theodorou, 2013; Jennings
et al., 2014; Olango and Finn, 2014; Aguilera et al., 2013; Mayer
et al., 2001b). Functional gastrointestinal disorders (FGIDs) such as
irritable bowel syndrome (IBS) are typiﬁed by heightened visceral
sensitivity as well as altered bowel movements and bloating.
Stressful life events both early in life and in adulthood have long
been implicated in the pathophysiology of IBS (Mayer, 2000; Mayer
et al., 2001a; McEwen, 1998; Fukudo, 2013). Indeed numerous
animal models used to investigate the pathogenesis of IBS are
stress-based models of visceral hypersensitivity (Larauche et al.,
2012; Moloney et al., 2015; Johnson and Greenwood-Van Meer-
veld, 2014). The potential role of glutamate in the nociceptive sig-
nalling of visceral stimuli has recently begun to be appreciated,
both at a spinal and supra-spinal level (Lindstrom et al., 2008;under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
R.D. Moloney et al. / Neurobiology of Stress 2 (2015) 28e33 29Crock et al., 2012a; Blackshaw et al., 2011; Cao et al., 2014; Zhou
et al., 2014).
Glutamate exerts its effects via ionotropic and metabotropic
(mGlu) receptors (Golubeva et al., 2015). Eight mGlu receptors have
been identiﬁed to date, which are sub-divided according to phar-
macology, signal transduction pathways and sequence homology
(Cartmell and Schoepp, 2000). mGlu receptors are not only
expressed centrally but offer promising pharmacological targets for
FGIDs as they are also expressed peripherally (Julio-Pieper et al.,
2011). Furthermore, mGlu receptors are now being looked at
more intensely as novel therapeutics not only for painful disorders
but also psychiatric disorders due to the more attractive safety
proﬁle in comparison to their ionotropic counterparts which
exhibit psychotomimetic side effects (Newcomer et al., 2000).
Recent evidence supports the concept of targeting group 1
metabotropic receptors (mGlu1, mGlu5) as a potential therapeutic
approach in animal models of visceral pain (Varty et al., 2005;
Neugebauer and Carlton, 2002; Blackshaw et al., 2011; Crock
et al., 2012b, 2012a). However, to date evidence for a role of
group III receptors, speciﬁcally the mGlu7 receptor, is lacking.
From an evolutionary standpoint, mGlu7 receptors are the most
highly conserved mGlu isoform (Flor et al., 1997). They are abun-
dantly distributed in the brain, especially in those regions, such as
the amygdala, known to be crucial for the emotional processing of
painful stimuli (O'Connor et al., 2010). The mGlu7 receptor is of
particular interest given that knockout and siRNA studies in mice
have indicated altered amygdala-dependent conditioned fear and
aversion responses (Callaerts-Vegh et al., 2006; Masugi et al., 1999;
Fendt et al., 2008), and reduced anxiety- and stress-related be-
haviours (Cryan et al., 2003). Moreover, mGlu7 receptor ablation
causes dysregulation of the hypothalamicepituitaryeadrenal (HPA)
axis and increases hippocampal brain derived neurotrophic factor
(BDNF) protein levels (Mitsukawa et al., 2006). More recently, the
development of a novel negative allosteric modulator (NAM) of
mGlu7 receptors, namely ADX71743 has been identiﬁed and char-
acterised showing potential anxiolytic effects in vivo (Kalinichev
et al., 2013). Taken together, these data may imply a potential role
for the mGlu7 receptor in the modulation of visceral hypersensi-
tivity which is comorbid with stress-related psychiatric disorders.
To this end, in the present study, we assessed whether
ADX71743 ((þ)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo
[d]oxazol-4(5H)-one), a potent, selective, and brain-penetrant
mGlu7 NAM (Kalinichev et al., 2013) could reduce visceral hyper-
sensitivity in the stress-sensitive Wistar Kyoto (WKY) rat strain.
This strain has previously been shown to exhibit visceral hyper-
sensitivity (Gunter et al., 2000; Carroll et al., 2013) in addition to
increased anxiety-like behaviours (Hyland et al., 2015). In addition,
previous in situ hybridization analysis from our lab has revealed
that the WKY rats displayed selective increases in mGlu7 receptor
mRNA expression in subregions of the hippocampus compared to
Sprague Dawley controls (O'Mahony et al., 2010a). Thus, we also
investigated whether negative modulation of mGlu7 could
ameliorate the anxiogenic proﬁle of this rat strain.
2. Materials and methods
2.1. Animals
Male WKY rats (250e300 g) (Harlan, UK) were used in this
study. All animals were group housed in plastic cages
(15  22  9 cm) and were maintained in a temperature controlled
room (20 ± 1 C) with a 12 h light/dark cycle. The animals were
allowed one week to acclimatise to the animal facility in University
College Cork after arrival. All experiments were conducted in
accordance with the European Directive 2010/63/EU and approvedby Animal Experimentation Ethics Committee of University College
of Cork.
2.2. Experimental design
Two cohorts of animals were used in the current study.
a) Cohort 1: ADX71743 or vehicle was administered 30 min prior
to colorectal distension (T0). Animals underwent the balloon
insertion protocol 10 min later (T10) and allowed to recover
until T30. Visceral pain behaviours were assessed at T30 and
immediately after, the animals were euthanized.
b) Cohort 2: ADX71743 or vehicle was administered 30 min prior
to the open ﬁeld test (T0). 15 min after administration, a blood
sample was taken (T15). The animals were introduced into the
open ﬁeld arena at T30. Animals were removed from the arena
after 10 min at T40. Repeated blood samples were taken
5 min later (T45), 30 min later (T75) and 15 min later (T90).2.3. Colorectal distension (CRD)
CRD was performed as previously described (O'Mahony et al.,
2010b; O'Mahony et al., 2012). Brieﬂy, animals were fasted over-
night (16 h) and on the day of testing, were anaesthetised with
isoﬂurane and a 6 cm latex balloon was inserted into the colorectal
cavity, 1 cm from the anus. The animals were allowed to recover for
20 min before CRD commenced. The paradigm used was an
ascending phasic distension from 0 mmHg to 80 mmHg over
8 min using a computer-driven electronic barostat (Dual Drive
Barostat, Distender Series II, G & J Electronics Inc., Toronto, ON,
Canada). The parameters of interest were: (1) the threshold pres-
sure (mmHg) that evokes visually identiﬁable visceral pain
behaviour and (2) the total number of pain behaviours. Postures
deﬁned as visceral pain behaviours were abdominal retractions
and/or abdominal withdrawal reﬂex. The treatment groups were
randomised and CRDwas performed by an experimenter blinded to
treatment groups.
2.4. Open ﬁeld
Animals were allowed to habituate to the testing room
30 min prior to commencing the test. The open ﬁeld apparatus
consisted of a white round arena measuring 90 cm diameter,
brightly lit to 1000 lux (Felice et al., 2014). Animals were introduced
in to the centre of the arena one at a time and allowed to explore for
10 min. Animals were then removed and placed immediately back
in their home cages. The arena was cleaned with 70% ethanol be-
tween each trial. Total distance travelled and the distance moved in
the inner zone were analysed using a tracking software system
(Ethovision, Noldus, The Netherlands). The treatment groups were
randomised and the open ﬁeld test was performed by an experi-
menter blinded to treatment groups.
2.5. Drug administration
ADX71743 was synthesised at Addex Therapeutics and kindly
donated to us. ADX71743 (50,100,150mg/kg) or vehicle (50% water
solution of hydroxyl-propyl-b-cyclodextrin (CD)) were adminis-
tered subcutaneously (s.c.) 30 min prior to commencement of
behavioural testing (Kalinichev et al., 2013). The suspensions were
homogenised with stainless steel balls for 30min at 30 Hz in a 2-ml
Eppendorf tube, and then vortexed and sonicated for 10 min. All
drugs dosed s.c. were administered at 3 ml/kg volume. Suspensions
were prepared fresh daily.
Fig. 1. ADX71743 attenuates visceral hypersensitivity in the stress-sensitive Wistar
Kyoto rat. Total pain behaviours [A] and sensitivity threshold [B]. (*p < 0.05, **p < 0.01,
***p < 0.001 vs vehicle, n ¼ 12/group).
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To estimate the magnitude of plasma corticosterone (CORT)
release upon exposure to a mild stressor, blood samples were
collected before and after the open ﬁeld protocol. Blood samples
(200 ml each) were taken from the tail vein immediately prior to
ADX71743 or vehicle administration (to determine baseline levels
of CORT, T0), 15 min after the injection (T15), and at T45, T75 and
T90 min after the open ﬁeld test.
2.7. Corticosterone analysis
CORT levels in plasma were measured by ELISA (Enzo Life Sci-
ences, Farmingdale, NY) according to the manufacturer's protocol.
2.8. Statistical analysis
All statistical tests were performed using SPSS 18. Graphing was
performed using GraphPad Prism 5. All data was normally
distributed according to Gaussian distribution analysis. Data are
expressed as mean ± SEM. One-Way-Analysis of Variance (ANOVA)
and LSD post hoc tests were used where appropriate. Stress-
induced changes in CORT levels were analysed in mixed designed
ANOVA with ADX71743 as a between-group factor and time as a
repeated-measured within-group factor. Further between-group
comparisons for each time point were done in one-way ANOVA
followed by Tukey's post hoc tests. A p value <0.05 was deemed
signiﬁcant in all cases. N ¼ 6e12/group.
3. Results
3.1. ADX71743 attenuates visceral hypersensitivity in the stress-
sensitive Wistar Kyoto rat
A one-way ANOVA analysis was performed to assess the effect of
ADX71743 on visceral hypersensitivity, (both total pain behaviours
and threshold). This revealed a signiﬁcant effect of drug treatment
for both total pain behaviours (F(3,30) ¼ 6.582, p < 0.01) and
threshold (F(3,30) ¼ 3.092, p < 0.05). Post hoc analysis revealed that
ADX71743 decreased total number of pain behaviours at all doses
(Fig. 1A) and increased threshold sensitivity at the 50 mg/kg and
100 mg/kg doses (Fig. 1B) in the hypersensitive WKY rat (*p < 0.05,
**p < 0.01, ***p < 0.001 vs vehicle).
3.2. ADX71743 attenuates anxiety-like behaviour in the stress-
sensitive Wistar Kyoto rat
A one-way ANOVA analysis was performed to assess the effect of
ADX71743 on anxiety behaviour in the open ﬁeld test, speciﬁcally
total distance travelled and distance travelled in the inner zone.
This revealed a signiﬁcant effect of drug treatment for both total
distance travelled (F(3,30) ¼ 5.936, p < 0.01) and distance travelled
in the inner zone (F(3,30) ¼ 6.395, p < 0.01). Post hoc analysis
revealed that ADX71743 increased the total distance travelled in the
open ﬁeld at doses of 50 mg/kg and 100 mg/kg (Fig. 2A). Moreover,
ADX71743 dose-dependently increased the distance travelled in the
inner zone of the open ﬁeld at all doses (Fig. 2B), (*p < 0.05,
**p < 0.01, ***p < 0.001 vs vehicle).
3.3. ADX71743 does not affect stress-induced corticosterone release
in the stress-sensitive Wistar Kyoto rat
Baseline CORT levels were similar across all groups (p > 0.05,
one-way ANOVA). Subcutaneous administration of either
ADX71743 or vehicle induced an increase in plasma levels of CORTin average by 20e50 ng/ml (Fig. 3, T15). The subsequent exposure of
animals to the novel arena stress under bright light resulted in a
pronounced CORT spike in all groups (increased by 90e120 ng/ml),
followed by a slow decline in CORT levels during the recovery
period. A mixed-design ANOVA analysis was performed to assess
the effect of ADX71743 on stress-induced corticosterone release.
This revealed neither signiﬁcant effect of drug treatment
(F(3,19) ¼ 0.67, p ¼ 0.581) nor signiﬁcant drug  time interaction
(F(12,76) ¼ 0.754, p ¼ 0.694).
4. Discussion
We found that the mGlu7 negative modulator ADX71743 nor-
malises visceral hypersensitivity in Wistar Kyoto rats as exhibited
by reduced total visceral pain behaviours with a concomitant in-
crease in the threshold to visceral sensitivity. Moreover, ADX71743
displays anxiolytic-like activity in the open ﬁeld with enhanced
total distance travelled and distance travelled in the inner zone.
This is to our knowledge the ﬁrst pharmacological study to impli-
cate mGlu7 in visceral pain processes.
The group III mGlu receptors are not only the largest mGlu re-
ceptor group but have also been the least investigated due to a lack
of selective pharmacological tools. The mGlu7 receptor is thought
Fig. 2. ADX71743 attenuates anxiety behaviour in the stress-sensitive Wistar Kyoto rat.
Total distance travelled [A] and distance travelled in the inner zone [B]. (*p < 0.05,
**p < 0.01, ***p < 0.001 vs control, n ¼ 7e8/group).
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acting to inhibit further release. Indeed, excessive glutamatergic
signalling has been shown to induce visceral pain behaviours
(Cervero, 2000). The mode of action of mGlu7 receptors may
lead us to postulate that their activation may be able to prevent
the process of central sensitisation and thus exhibit analgesic
properties. Indeed, treatment with mGlu7 receptor ligands such
as mGlu7 receptor agonist, N,N(I)-dibenzhydrylethane-1,2-diaminFig. 3. ADX71743 does not signiﬁcantly alter the stress-induced corticosterone
response in the stress-sensitive Wistar Kyoto rat (n ¼ 6/group).dihydrochloride (AMN082) signiﬁcantly inhibited both early and
late phase formalin-induced hyperalgesia and pain behaviours
(Dolan et al., 2011). Intrathecal injection of AMN082 post-
carrageenan and post-surgery also signiﬁcantly attenuated ther-
mal hyperalgesia (Dolan et al., 2009). AMN082 has also been shown
to decrease responses in a model of cardiac nociception (Liu et al.,
2012). However, conﬂicting evidence has also emerged showing
that AMN082 induces a hyperalgesic response in both the hotplate
and tail ﬂick assays (G et al., 2014)
However, although initially thought to be a useful tool to assess
mGlu7 function (Mitsukawa et al., 2005; Fendt et al., 2008;
O'Connor and Cryan, 2013) the ﬁnding that AMN082 has metabo-
lites with strong monoamine activity (Sukoff Rizzo et al., 2011)
detracts from it's overall utility. The current ﬁnding that negative
modulation of mGlu7 receptors using ADX71743 ameliorates
visceral pain is somewhat paradoxical as mGlu7 receptors act as
auto-receptors to inhibit neurotransmitter release. By blocking
mGlu7 receptors, one would assume that its auto-receptor function
and thereby inhibitory effects on glutamate release would be pre-
vented thus leading to excessive glutamate release into the syn-
apse. However, similar ﬁndings have been reported by others using
6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo[4,5-c]
pyridin-4(5H)-one (MMPIP), an mGlu7 receptor negative allosteric
modulator. It was found to block the ﬁrst and second phase of
nocifensive behaviour in the formalin pain model and increase tail
ﬂick latency (Palazzo et al., 2013).
Moreover, it is important to note that the effects seen in this
study can be attributed to both central and peripheral sites of ac-
tion. Further studies are required to fully elucidate the exact role of
mGu7 receptors in the pathophysiology of visceral pain and to
more accurately ascertain whether these analgesic effects are
mediated peripherally or centrally. Indeed the complex pharma-
codynamic properties of ADX71743 also require further investiga-
tion as eluded to in the 150 mg/kg treatment group, whereby its
effects are less than that seen in the lower dose groups (50 and
100 mg/kg). This bell shaped curve suggests that lower doses of
ADX71743 may prove more efﬁcacious in the context of visceral
pain and anxiety in the Wistar Kyoto model.
Similar questions arise when understanding why ADX71743
reduces anxiety behaviours in the open ﬁeld test. Indeed compa-
rable results have also been described by others, whereby
ADX71743 was shown to decrease anxiety in the marble burying
and elevated plus maze (EPM) tests (Kalinichev et al., 2013).
Moreover, mGlu7 receptor knockout mice displayed anxiolytic-like
behaviour in the lightedark box, EPM, marble burying test, the
staircase test, and stress-induced hypothermia (SIH), as well as
showing deﬁcits in retention and extinction of conditioned fear
(Callaerts-Vegh et al., 2006; Fendt et al., 2013; Cryan et al., 2003).
Furthermore, mGlu7 receptor knock-down in adult brain using
siRNA, reduced innate anxiety in the lightedark box, attenuated
SIH response and fear-potentiated startle response (O'Connor et al.,
2013). Moreover, ADX71743 has previously been evaluated in ro-
dent models of psychosis again highlighting the regional local-
isation of mGlu7 within the mammalian CNS (Kalinichev et al.,
2013). Although it is widely distributed throughout the brain,
mGlu7 receptor shows particularly high abundance in the
neocortex, piriform and entorhinal cortices, hippocampus, amyg-
dala, globus pallidus, ventral pallidum, and the locus coeruleus
(Kinoshita et al., 1998). Abnormalities in these regions have been
linked to anxiety disorders (Walker and Davis, 2002), depression
(Sanacora et al., 2012) and psychosis (Moghaddam and Adams,
1998) among other CNS disorders.
Recently, it was also postulated that the anxiolytic actions of
ADX71743 may possibly involve the HPA axis (Kalinichev et al.,
2013). This was based on ﬁndings from (Mitsukawa et al., 2006),
R.D. Moloney et al. / Neurobiology of Stress 2 (2015) 28e3332showing that mGlu7 receptor knockout mice exhibit signs of HPA
axis dysregulation, including up-regulation of glucocorticoid and 5-
HT1A receptors in the hippocampus, increased sensitivity to
glucocorticoid-mediated negative feedback, and increases in BDNF
protein in the hippocampus (Mitsukawa et al., 2006). These
changes at a molecular level may indeed go towards explaining
what is seen at a behavioural level with mGlu7 receptor KO animals
exhibiting reduced anxiety- and depression-like behaviours (Cryan
et al., 2003).
These ﬁndings suggest that inhibition of mGlu7 receptor sig-
nalling with ADX71743 would decrease the activity of the HPA axis.
However, in the present study we did not observe a signiﬁcant
effect of ADX71743 on the HPA axis reactivity as estimated by
similar magnitude of corticosterone release in response to an acute
novelty stressor and the equal rate of post-stress recovery in the
ADX71743-treated animals. These data somehow contradicts the
results of previous study with subtype-nonselective group III re-
ceptor agonists (L-AP4, L-SOP) showing increased circulating levels
of corticosterone in rats upon agonist treatment (Johnson et al.,
2001). However, we should note that anxiolytic-like effect of
different group III receptor modulators (such as AMN082, Lu
AF21934, LSP1-2111, CPPG) has been shown to implicate different
neurotransmitter systems (GABA, serotonin, or combination of
both) (Stachowicz et al., 2007, 2008; Slawinska et al., 2013;
Wieronska et al., 2010). This can potentially contribute to the dif-
ferential role of ADX71743 vs L-AP4/L-SOP in regulation of the HPA
axis. Also, in the study by Johnson et al., SpraqueeDawley rats, an
outbred strain, were used, which is believed to be more resilient to
stress compared to the stress-sensitive WKY rat strain utilised in
our study. Indeed our previous studies have shown that WKY ani-
mals have different physiological and behavioural response to early
life and immune stressors (O'Mahony et al., 2013; Hyland et al.,
2015; Felice et al., 2014). Genetically determined differences in
the activity of stress-related neural circuits in these two strains
could also underlie the observed discrepancies in the effects of
ADX71743 and L-AP4/L-SOP on the HPA axis activity. Further
studies utilizing various mGlu7 receptor ligands and different ani-
mal models are required to address the questionwhether inhibition
of mGlu7 receptor can lead to alterations in the HPA axis.
Finally, we do not know whether the anti-nociceptive effects of
ADX71743 are speciﬁc to stress-induced visceral pain and whether
they generalise to other pain modalities. Future studies in this re-
gard will also aid in unravelling the role of mGlu7 in pain processes.
Furthermore, it is pertinent to note that in the current study the
stress of drug administration via subcutaneous injection, had an
impact on behavioural phenotypes in terms of both visceral
sensitivity and anxiety-like behaviour.
Taken together, the data presented here add further evidence for
the role of glutamate in the pathophysiology of visceral pain and
moreover the use of ADX71743 as a promising new therapeutic for
pain in functional bowel disorders with comorbid anxiety. How-
ever, the exact molecular mechanism bywhich ADX71743mediates
its effects must ﬁrst be elucidated.
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